Acquisition of the constitutively active Janus kinase 2 (JAK2)V617F mutation occurs in almost all patients with polycythaemia vera (PV) and in a significant number of patients with essential ...
In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...
Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.
Dizal announces new findings on golidocitinib; to present clinical results at ELCC 2025 in Paris on March 26-29: Shanghai Saturday, March 22, 2025, 17:00 Hrs [IST] Dizal, a biopha ...
ORLANDO, FLA. — Janus kinase (JAK) inhibitors have revolutionized the treatment of alopecia areata (AA), and more drugs in this class are still in development for AA. However, a new therapy with ...
Golidocitinib is currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical ...
ATOPIC dermatitis (AD) is the most common chronic inflammatory skin condition, affecting up to 10% of adults and up to 20% of ...
Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback